134 related articles for article (PubMed ID: 37646148)
21. Targeting an elevated FVIII level using personalized rurioctocog alfa pegol prophylaxis in specific patient populations with hemophilia A:
Escuriola-Ettingshausen C; Klamroth R; Escobar M; Stasyshyn O; Tangada S; Engl W; Honauer I; Lee HY; Chowdary P; Windyga J
Ther Adv Hematol; 2023; 14():20406207231178596. PubMed ID: 37465396
[TBL] [Abstract][Full Text] [Related]
22. Evaluation of collagen turnover biomarkers as an objective measure for efficacy of treatment with rurioctocog alfa pegol in patients with hemophilia A: a secondary analysis of a randomized controlled trial.
Manon-Jensen T; Tangada S; Bager C; Chowdary P; Klamroth R; von Drygalski A; Windyga J; Escobar M; Frederiksen P; Engl W; Ewenstein B; Karsdal M
J Thromb Haemost; 2024 Jan; 22(1):90-100. PubMed ID: 37717853
[TBL] [Abstract][Full Text] [Related]
23. Comparison of Real-World Dose and Consumption for Two Extended Half-Life Recombinant Factor VIII Products for the Treatment of Hemophilia A in the United States.
Wu Y; Sun SX; Fan T
J Blood Med; 2022; 13():517-524. PubMed ID: 36188439
[TBL] [Abstract][Full Text] [Related]
24. Results from a large multinational clinical trial (guardian™1) using prophylactic treatment with turoctocog alfa in adolescent and adult patients with severe haemophilia A: safety and efficacy.
Lentz SR; Misgav M; Ozelo M; Salek SZ; Veljkovic D; Recht M; Cerqueira M; Tiede A; Brand B; Mancuso ME; Seremetis S; Lindblom A; Martinowitz U
Haemophilia; 2013 Sep; 19(5):691-7. PubMed ID: 23647704
[TBL] [Abstract][Full Text] [Related]
25. A post hoc analysis of PROTECT VIII kids assessing long-term efficacy and safety of damoctocog alfa pegol in adolescents with severe haemophilia A.
Ahuja S; Biss T; Maas Enriquez M; Mancuso ME; Steele M; Kenet G
Eur J Haematol; 2024 May; 112(5):756-764. PubMed ID: 38193596
[TBL] [Abstract][Full Text] [Related]
26. Low incidence of factor VIII inhibitors in previously untreated patients during prophylaxis, on-demand treatment and surgical procedures, with Octanate®: interim report from an ongoing prospective clinical study.
Klukowska A; Komrska V; Jansen M; Laguna P
Haemophilia; 2011 May; 17(3):399-406. PubMed ID: 21118334
[TBL] [Abstract][Full Text] [Related]
27. Long-term safety and efficacy of turoctocog alfa in prophylaxis and treatment of bleeding episodes in severe haemophilia A: Final results from the guardian 2 extension trial.
Lentz SR; Janic D; Kavakli K; Miljic P; Oldenburg J; C Ozelo M; Santagostino E; Suzuki T; Zupancic Šalek S; Korsholm L; Matytsina I; Tiede A
Haemophilia; 2018 Nov; 24(6):e391-e394. PubMed ID: 30402994
[TBL] [Abstract][Full Text] [Related]
28. Damoctocog Alfa Pegol: A Review in Haemophilia A.
Paik J; Deeks ED
Drugs; 2019 Jul; 79(10):1147-1156. PubMed ID: 31218660
[TBL] [Abstract][Full Text] [Related]
29. Phase 4 Safety and Efficacy Study of Antihemophilic Factor (Recombinant) in Previously Treated Chinese Patients With Severe/Moderately Severe Hemophilia A.
Zhao Y; Hu Y; Jin J; Zhao X; Wang X; Wu R; Wu D; Yang R; Yang F; Hu Q; Wang J; Fang H; Engl W
Clin Appl Thromb Hemost; 2021; 27():1076029621989811. PubMed ID: 33587652
[TBL] [Abstract][Full Text] [Related]
30. Interim analyses of the multinational real-world prospective cohort HEM-POWR study evaluating the effectiveness and safety of damoctocog alfa pegol in patients with hemophilia A.
Reding MT; Álvarez-Román MT; Castaman G; Janbain M; Matsushita T; Meijer K; Schmidt K; Oldenburg J
Eur J Haematol; 2024 Feb; 112(2):286-295. PubMed ID: 37876046
[TBL] [Abstract][Full Text] [Related]
31. Long-Term Outcomes of Previously Treated Adult and Adolescent Patients with Severe Hemophilia A Receiving Prophylaxis with Extended Half-Life FVIII Treatments: An Economic Analysis from a United Kingdom Perspective.
Benson G; Morton T; Thomas H; Lee XY
Clinicoecon Outcomes Res; 2021; 13():39-51. PubMed ID: 33500640
[TBL] [Abstract][Full Text] [Related]
32. Simoctocog alfa (Nuwiq®) in previously untreated patients with severe haemophilia A-Final efficacy and safety results from the NuProtect study.
Mathias M; Abraham A; Belletrutti MJ; Carcao M; Carvalho M; Chambost H; Chan AKC; Dubey L; Ducore J; Gattens M; Gresele P; Gruel Y; Guillet B; Jiménez-Yuste V; Kitanovski L; Klukowska A; Lohade S; Mancuso ME; Oldenburg J; Pollio B; Sigaud M; Vilchevska K; Wu JKM; Jansen M; Belyanskaya L; Walter O; Knaub S; Neufeld EJ
Eur J Haematol; 2023 Oct; 111(4):544-552. PubMed ID: 37439123
[TBL] [Abstract][Full Text] [Related]
33. BAY 81-8973 Efficacy and Safety in Previously Untreated and Minimally Treated Children with Severe Hemophilia A: The LEOPOLD Kids Trial.
Ljung R; Chan AKC; Glosli H; Afonja O; Becker B; Tseneklidou-Stoeter D; Mancuso ME; Saulyte-Trakymiene S; Kenet G
Thromb Haemost; 2023 Jan; 123(1):27-39. PubMed ID: 36626898
[TBL] [Abstract][Full Text] [Related]
34. Zero incidence of factor VIII inhibitors and successful haemostatic response in previously factor VIII-treated patients with haemophilia A switching to turoctocog alfa in a noninterventional study.
Escuriola Ettingshausen C; Katsarou O; Kotnik BF; Borel Derlon A; Schwarz R; Ypma PF; Matytsina I; Dey S; Schutgens REG
Haemophilia; 2022 Jan; 28(1):46-54. PubMed ID: 34791736
[TBL] [Abstract][Full Text] [Related]
35. Prospective surveillance study of haemophilia A patients switching from moroctocog alfa or other factor VIII products to moroctocog alfa albumin-free cell culture (AF-CC) in usual care settings.
Parra Lopez R; Nemes L; Jimenez-Yuste V; Rusen L; Cid AR; Charnigo RJ; Baumann JA; Smith L; Korth-Bradley JM; Rendo P
Thromb Haemost; 2015 Oct; 114(4):676-84. PubMed ID: 26293201
[TBL] [Abstract][Full Text] [Related]
36. Efficacy and safety of rVIII-SingleChain: results of a phase 1/3 multicenter clinical trial in severe hemophilia A.
Mahlangu J; Kuliczkowski K; Karim FA; Stasyshyn O; Kosinova MV; Lepatan LM; Skotnicki A; Boggio LN; Klamroth R; Oldenburg J; Hellmann A; Santagostino E; Baker RI; Fischer K; Gill JC; P'Ng S; Chowdary P; Escobar MA; Khayat CD; Rusen L; Bensen-Kennedy D; Blackman N; Limsakun T; Veldman A; St Ledger K; Pabinger I;
Blood; 2016 Aug; 128(5):630-7. PubMed ID: 27330001
[TBL] [Abstract][Full Text] [Related]
37. Efficacy, safety and pharmacokinetics of recombinant human coagulation factor VIII (omfiloctocog alfa) in previously treated Chinese children with severe hemophilia A.
Wu R; Wang X; Zhao X; Cheng Y; Zhou Z; Sun J; Xu M; Li W; Xiao J; Yang F; Chen Y; Xu W; Huang J; Ma C; Gai W; Xie L; Yang R
Haemophilia; 2022 Nov; 28(6):e199-e208. PubMed ID: 35802040
[TBL] [Abstract][Full Text] [Related]
38. Efanesoctocog Alfa Prophylaxis for Patients with Severe Hemophilia A.
von Drygalski A; Chowdary P; Kulkarni R; Susen S; Konkle BA; Oldenburg J; Matino D; Klamroth R; Weyand AC; Jimenez-Yuste V; Nogami K; Poloskey S; Winding B; Willemze A; Knobe K;
N Engl J Med; 2023 Jan; 388(4):310-318. PubMed ID: 36720133
[TBL] [Abstract][Full Text] [Related]
39. Results from a large multinational clinical trial (guardian™3) using prophylactic treatment with turoctocog alfa in paediatric patients with severe haemophilia A: safety, efficacy and pharmacokinetics.
Kulkarni R; Karim FA; Glamocanin S; Janic D; Vdovin V; Ozelo M; Rageliene L; Carboni E; Laguna P; Dobaczewski G; Seremetis S; Lindblom A; Santagostino E
Haemophilia; 2013 Sep; 19(5):698-705. PubMed ID: 23651313
[TBL] [Abstract][Full Text] [Related]
40. Pharmacokinetics, immunogenicity, safety, and preliminary efficacy of subcutaneous turoctocog alfa pegol in previously treated patients with severe hemophilia A (alleviate 1).
Klamroth R; Feistritzer C; Friedrich U; Lentz SR; Reichwald K; Zak M; Chowdary P
J Thromb Haemost; 2020 Feb; 18(2):341-351. PubMed ID: 31618804
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
